Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers
- 10 April 2005
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (11) , 2460-2468
- https://doi.org/10.1200/jco.2005.00.661
Abstract
Purpose Greater understanding of the cellular response in trastuzumab-treated patients will provide insight into the clinical management of patients. Patients and Methods We performed a neoadjuvant...Keywords
This publication has 20 references indexed in Scilit:
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer CellsCancer Research, 2004
- Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast CancerBreast Cancer Research and Treatment, 2003
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Biological Effects of Anti-ErbB2 Single Chain Antibodies Selected for Internalizing FunctionBiochemical and Biophysical Research Communications, 2001
- Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinomaCancer, 2000
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathwayOncogene, 1997
- Cell kinetics in human breast cancer: Comparison between the prognostic value of the cytofluorimetric S‐phase fraction and that of the antibodies to Ki‐67 and PCNA antigens detected by immunocytochemistryInternational Journal of Cancer, 1994